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The staging and prognosis of oropharyngeal squamous cell carcinoma is intimately tied to the status of the cervical lymph nodes.
Due to the high risk for occult nodal disease, most clinicians recommend treating the neck for these primary tumors. While there
aremanymodalitiesavailable,surgicalresectionofnodaldiseaseoﬀersbothatherapeuticandadiagnosticintervention.Wereview
the relevant anatomy, nodal drainage patterns, clinical workup, surgical management and common complications associated with
neck dissection for oropharyngeal squamous cell carcinoma.
1.Introduction
Each year, 5000 new cases of oropharyngeal cancer are
diagnosed in the US, and 85–90% of these are conﬁrmed as
squamous cell carcinoma (SCC) [1]. Cervical lymph node
status remains the most important prognosticator in head
and neck squamous cell carcinoma (HNSCC) in the absence
of distant metastases, reducing 5-year survival by 50% [2, 3].
While the choice of management for occult metastases is
complex, most clinicians agree that treatment should be
chosen over observation when the risk of occult disease is
20% or greater [4]. The incidence of occult metastases in
clinically node-negative necks (cN0) in OPSCC has been
reported to be greater than 30% in some series [5, 6]. The
importance of assessing and managing the cervical nodal
basin in OPSCC is therefore of utmost importance and is the
focus of the current paper.
2. Anatomy and Lymphatic Drainageof
the Oropharynx
Prognosis for patients with OPSCC is closely associated
with the involvement of cervical lymph nodes. Therefore,
an understanding of the anatomical subsites and lymphatic
drainage patterns of each is crucial. The oropharynx is
bounded by the posterior edge of the hard palate superiorly,
the pharyngeal wall posteriorly, the tonsillar complexes
(including the anterior and posterior tonsillar pillars, true
tonsil, and tonsillar fossa) laterally, the circumvallate papillae
and palatoglossal muscles anteroinferiorly, and the vallecula
and hyoid bone inferiorly. The surgical anatomy of this area
is classically divided into four distinct subsites: (1) base of
tongue (BOT), (2) soft palate, (3) tonsillar complex, and
(4) posterior pharyngeal wall (PPW) [7]. These subsites
are independently important, and as Lindberg stated in his
classic work on lymphatic drainage patterns in the head and
neck, “metastases from primary lesions of the oropharynx
have some common locales [8].” A thorough understanding
of these drainage patterns is a prerequisite to the surgical
neck dissection (ND) for OPSCC.
2.1. Base of Tongue. The BOT can be deﬁned anteriorly
by the circumvallate papillae, laterally by the glossopalatine
sulci, and inferiorly by the vallecula [9]. This area includes
the pharyngoepiglottic folds as well as the glossoepiglottic
fold [10]. The lymphatics of the BOT drain primarily to
the upper two thirds of the jugular lymphatic chain, often
bilaterally [7]. Hollinshead stated that the lymphatics poste-
rior to the vallate papillae drained to the nodes of the upper
part of the deep cervical chain, with a predilection for the
jugulodigastric node [11]. Lindberg associated the midline
position of the BOT with the frequency of bilateral cervical2 ISRN Surgery
node involvement [8]. In his report, bilateral subdigastric
node involvement was more common than midjugular node
involvement, posterior cervical nodal disease was uncom-
mon, and low jugular or supraclavicular nodes were rare [8].
2.2. Soft Palate. The soft palate is deﬁned anteriorly by the
hard palate, laterally by the palatopharyngeal and superior
pharyngeal constrictor muscles, and posteriorly by the
palatopharyngeal arch and uvula. The lymphatics of the soft
palate have three distinct systems, which drain (1) medially
to the middle third of the jugular chain, (2) laterally to
the retropharyngeal (RP) lymphatics, and (3) anteriorly to
the hard palate and subsequently into the submental and
submandibular nodal groups [7] .T h el y m p h a t i c si nt h e
uvula drain primarily into the upper jugular chain, while
the vessels draining the upper or posterior surface of the
soft palate drain laterally via the pharyngeal lymphatics to
end in the RP nodes [11]. Lindberg found that, as a midline
structure, the incidence of bilateral metastases in OPSCC of
the soft palate was high, with the jugular nodes the most
frequently involved [8].
2.3. Posterior Pharyngeal Wall. The PPW spans the area
deﬁned by the soft palate, the epiglottis, the borders of the
tonsillar complexes, and the lateral aspects of the piriform
sinuses inferiorly [9]. The lymphatic drainage from the PPW
is primarily via the jugular chain bilaterally to the upper
jugular nodes in the subdigastric group [8]. The midjugular
group is also frequently involved, as is the posterior cervical
triangle, while supraclavicular disease is rare [8].
2.4.TonsillarComplex. Thetonsillarcomplexiscomposedof
the anterior and posterior tonsillar pillars, the true palatine
tonsil, and the tonsillar fossa. Primary tumors of the tonsillar
complex frequently metastasize to the lateral RP nodes and
the upper third of the ipsilateral jugular lymphatic chain,
with a smaller proportion draining to the middle third of the
jugularlymphaticchain[7].Lindbergfoundthatthetonsillar
node,withinthesubdigastricgroup,wasalwaysinvolvedﬁrst
in cervical metastasis [8]. He also found that both mid and
low jugular nodes were frequently involved, and metastases
within the posterior cervical triangle were not uncommon
[8].
2.5. Potential Spaces. When considering oncology of the
oropharynx, it is also important to understand the asso-
ciation of two relevant potential spaces. The RP space is
located posterior to the oropharynx behind the pharyngeal
constrictors. Invasion into this space by OPSCC signiﬁcantly
increases the risk of bilateral regional metastases [1]. RP
nodes are most commonly involved in PPW OPSCC. Bal-
lantyne reported positive RP nodes in 44% of patients
with OPSCC in this subsite [12]. Hasegawa and Matsuura
reviewed 11 cases of stage III/IV OPSCC and concluded
that carcinoma of the oropharynx drains directly to the RP
nodes, and therefore the evaluation of the RP lymph nodes
is critical in the assessment of SCC of the pharynx [13]. The
second space, the parapharyngeal space, is important when
considering lateral spreading tumors. This space is often
described as an inverted pyramid bounded by the skull base,
lateral pharyngeal constrictors, and hyoid cornu [14].
3. Nodal Classiﬁcation
Despite a careful understanding of the anatomy and lym-
phatic drainage patterns of subsites within the oropharynx,
there is a wide variety of individual anatomy and incidence
of cervical nodal involvement. A careful understanding of
the classiﬁcation system presented by the Memorial-Sloan
Kettering Group [15] and further modiﬁed by the American
Head and Neck Society’s Neck Dissection Committee [16]i s
therefore warranted. This classiﬁcation system contains six
levels, with level I, II, and V divided into two subgroups
designated either A or B and is based largely on the
biologic signiﬁcance of positive nodes [7]. Each level has a
general name describing the group of lymph nodes within
its boundaries and deﬁned borders based on anatomic,
radiologic, and surgical landmarks [17]. We will focus our
review on the surgical landmarks deﬁning each level. The
frequency of nodal involvement in OPSCC based on this
classiﬁcation system is reviewed in Table 1.
The submental lymph nodes make up level IA. They can
be found within the submental triangle, which is bounded
laterally by the anterior bellies of the digastric muscles,
inferiorly by the hyoid, and superiorly by the mandibular
symphysis [17]. The ﬂoor of this space is formed by the
mylohyoid muscle. The submandibular lymph nodes are
found in level IB as deﬁned surgically by the body of
the mandible superiorly, the digastric tendon attachment
to the hyoid bone inferiorly, the anterior belly of the
digastric muscle anteriorly, and by the posterior edge of the
submandibular gland posteriorly [17].
Level II deﬁnes the superior jugular lymph nodes and is
divided into Level IIA and IIB by the spinal accessory nerve.
Level IIA is deﬁned superiorly by the skull base, inferiorly by
the carotid bifurcation (or the inferior border of the hyoid
bone), posterolaterally by a vertical plane deﬁned by the
spinal accessory nerve (SAN), and anteriorly by the posterior
border of the submandibular gland [17]. Level IIB is referred
to as the submuscular recess or posterior triangle apex. It
is deﬁned superiorly by the skull base, inferiorly by the
carotidbifurcation(ortheinferiorborderofthehyoidbone),
laterallybythesternocleidomastoidmuscle,andanteriorlyor
medially by the vertical plane deﬁned by the path of the SAN
[17]. Its ﬂoor is deﬁned by the splenius capitus muscle [18].
The midjugular lymphatic group, or level III, is deﬁned
superiorly by the carotid bifurcation, inferiorly by the
omohyoid muscle, laterally by the sensory branches of the
cervical plexus, and medially by the sternohyoid muscle [17].
Level IV is described as the inferior jugular nodes and
is deﬁned superiorly by the omohyoid muscle, inferiorly by
the clavicle, laterally by the sensory branches of the cervical
plexus of nerves or the lateral border of the sternocleidomas-
toid muscle, and medially by the sternohyoid muscle [17].
Level V is again subdivided into level VA and VB. It
deﬁnes the posterior triangle lymph node group and is
variably involved in OPSCC. Level VA is deﬁned superiorlyISRN Surgery 3
Table 1: Frequency nodal level involvement in OPSCC based on ipsilateral versus contralateral neck evaluation (A), as well as clinical nodal
status (B).
A. Study Site Level I (A/B) Level II (A/B)∗ Level III Level IV Level V (A/B)∗
Ipsi (%) Contra
(%) Ipsi (%) Contra
(%) Ipsi (%) Contra
(%) Ipsi (%) Contra
(%) Ipsi (%) Contra
(%)
Gr´ egoire
and Lee
[19]
OPSCC 1 3 28 22 42 3 5 9 2 1 33
Lindberg
[8]
Soft Palate (1.3/ 2.5) (1.3/1.3) 37.5 12.5 11.3 2.5 2.5 0 0 1.3
Tonsillar Fossa (0.7/1.4) (0/2.1) 73.6 10 17.9 6.4 10 1.4 10 3.6
BOT (1.1/5.4) (0.5/0) 68.6 24.3 30.8 54.1 7 2.2 8.6 2.2
Oropharyngeal Walls (1.3/3.4) (0/0) 52.3 14.1 20.8 3.4 4.7 2 9.4 4
Lim et al.
[22]
OPSCC 83 57 45 50
B. Study
Level I Level II∗ Level III Level IV Level V∗
cN0 (%) cN+ (%) cN0
(%) cN+ (%) cN0
(%) cN+ (%) cN0
(%) cN+ (%) cN0 (%) cN+
(%)
MSK∗∗ OPSCC 2 1 5 2 57 51 94 2 8 2 7 2 9
Lim et al.
[22]
OPSCC 09 . 9 33 5
Ipsi: ipsilateral neck; Contra: contralateral neck; cN0: clinically negative neck; cN+: clinically positive neck; OPSCC: oropharyngeal squamous cell carcinoma;
BOT: base of tongue.
∗The importance of level IIB and V in OPSCC is discussed in the text under the subheading “Sequelae.”
∗∗MSK: data from the Head and Neck Department at Memorial Sloan-Kettering Cancer Center as presented by Gr´ egoire and Lee [19].
by the junction of the SCM and the trapezius muscle,
inferiorly by the horizontal plane deﬁned by the inferior
border of the cricoid cartilage, laterally by the anterior
border of the trapezius muscle, and medially by the sensory
branchesofthecervicalnerveplexus[17].LevelVBisdeﬁned
superiorly by the horizontal plane of the inferior border of
the cricoid cartilage, inferiorly by the clavicle, laterally by the
anterior border of the trapezius, and medially by the sensory
branches of the cervical plexus [17].
Level VI, known as the anterior or central neck compart-
ment, is important to deﬁne for completeness but is rarely
involved in OPSCC [17]. It is deﬁned superiorly by the hyoid
bone, inferiorly by the superior edge of the manubrium of
the sternum, and bilaterally by the common carotid arteries
[19].
4. DiagnosticEvaluationof the Neck in OPSCC
Staging the neck using the nodal levels described above, as
wellastheTNMsystemrecommendedbytheAmericanJoint
Commission on Cancer (AJCC) (Table 2), is a prerequisite
for surgical management of the neck in OPSCC [20].
The National Comprehensive Cancer Network (NCCN)
includes the following in their 2011 guidelines for the
evaluation of the neck in OPSCC: history and physical,
biopsy,HPVtestingforprognosis(suggested),chestimaging,
computed tomography (CT) with contrast and/or magnetic
resonance imaging (MRI) of both the primary site and neck,
18-ﬂuorodeoxyglucose positron emission tomography and
Table 2: Nodal staging of OPSCC based on the American Joint
Commission on Cancer [20].
Stage Nodal involvement
NX The neck cannot or was not assessed.
N0 No nodal metastases; neck was evaluated.
N1 Single node, ipsilateral to primary tumor; ≤3cm.
N2a Single node, ipsilateral to primary tumor; 3–6cm.
N2b Multiple nodes, ipsilateral to primary tumor; ≤6cm.
N2c Single or multiple node; contralateral neck involved; all
≤6cm.
N3 One or more nodes > 6cm regardless of multiplicity or
laterality.
computed tomography (PET-CT) for stage III–IV (consid-
eration), dental evaluation as indicated, and examination
under anesthesia with endoscopy as clinically indicated [21].
Physical examination and palpation of the neck has
a relatively low sensitivity and speciﬁcity for diagnosing
lymphatic metastasis [23]. McGuirt et al. reported the
sensitivity of palpation alone to be 70% [24]. The addition of
CTscanstoclinicalﬁndings increasesdiagnostic detection to
80% with an accuracy of 70–80% [25]. According to Cohan
et al., MRI oﬀers superior soft tissue contrast, increased
resolution of bone marrow involvement, and improved
resolution of perineural spread compared to CT [14].
Shingaki et al. concluded that the addition of CT, MRI, and
biopsy topalpationincreasesthediagnostic valueforcervical4 ISRN Surgery
disease [26]. A relatively new addition to the diagnostic
armamentarium is PET-CT. This modality has been shown
toassistinthediagnosisanddetectionofregionalanddistant
metastases in HNSCC [27, 28]. PET-CT has an average
sensitivity of 87–90% and speciﬁcity of 80–93% [29, 30].
This tool can be used to guide dissection of high-risk areas
outside the bounds of the routine ND [31]. However, PET-
CT is limited by a relatively low resolution (4-5mm), high
false positive rate, cost, and interobserver variability [32].
Despiteadvancesintechnology, thegoldstandardforstaging
the neck remains histopathologic tissue analysis. Rodrigo et
al. note that even the most recent techniques of CT, MRI,
ultrasonography, PET-CT, and ultrasound guided FNA have
reached a sensitivity of no more than 80–85% [33]. The
primary limitation of these studies appears to be the inability
to detect micrometastases [34].
Pathology of the neck specimens provides information
regarding size of metastases, number of involved nodes,
presence of extracapsular spread (ECS), additional tumor
deposits, and micrometastases [2]. However, despite the
routineuseofpathologicstagingandourdependenceonitas
the gold standard for staging the neck, Shah and Gil. report
the risk of recurrence in the pathologically node-negative
( p N 0 )n e c kt ob ea sh i g ha s1 0 %[ 35]. This is relevant
in that the diagnosis of a false negative pN0 is associated
with a poor prognosis [36]. This has spurned investigation
into the use of molecular markers which might improve
diagnostic accuracy. Using reverse transcriptase polymerase
chain reaction (RT-PCR), Seethala found that 20–30% of
pN0 necks by light microscopy and immunohistochemistry
(IHC) were “molecular positive” [2]. This technique is
limited by a high false positive rate, the requirement of
frozen specimens, the loss of morphologic comparison, and
the lack of a deﬁned or consistent “threshold” for positivity
[2]. Some authors hypothesize that further understanding
of micrometastases, isolated tumor cells, and molecular
characteristics may help to explain a subset of the 10% of
regional recurrences in the neck despite a pN0 designation
based on light microscopy and IHC [2]. In addition, further
research into the use of additional markers and the use of a
multiplex approach to diagnosis could help explain regional
failures not explained by surgical failure and nonlymphatic
spread of disease [2, 37].
The inability of routine pathologic analysis to detect
100% of tumor and the associated morbidity associated with
routine ND has led to investigation into the use of sentinel
lymph node biopsy (SLN) for staging the neck in OPSCC.
Ferlito et al. suggest that since only 25–30% of cN0 necks are
upstagedtopN+necksfollowingND,themajorityofelective
surgical management has no therapeutic beneﬁt other than
to conﬁrm clinical staging [38]. Furthermore, Burcia et al.
suggest that while SLN sampling allows the pathologist to
focus their eﬀorts on a smaller tissue sample, routine staging
methods requiring evaluation of large neck specimens leads
to a high rate of false negatives and may underestimate
the number of invaded lymph nodes per patient [39]. The
Second International Conference on Sentinel Node Biopsy
In Mucosal Head and Neck Cancer suggested that SLN
biopsy can be used in the following settings: (1) staging of
the ipsilateral neck in unilateral cT1/T2 cN0 tumors, (2)
staging of the ipsilateral and contralateral neck in cT1/T2
cN0 midline tumors or tumors crossing the midline, and (3)
staging of the contralateral neck in cT1/T2 cN+ (ipsilateral
neck) midline tumors or tumors crossing the midline [40].
Regardless of the potential for this staging modality, its
routine use in the management of the neck in OPSCC is still
inadequately deﬁned.
5. Neck Dissection
5.1. Past and Present History. A discussion regarding surgical
management of the neck in OPSCC cannot be undertaken
without ﬁrst reviewing its history. The importance of nodal
involvement in head and neck cancers was ﬁrst reported in
themedicalliteratureinthe18thcenturyandwasconsidered
a sign of incurable disease until the mid-1800s [41]. In 1880,
Kocher presented the ﬁrst description of removing cervical
nodes in the submandibular triangle to access a cancer of
the tongue [42]. The ﬁrst documented ND was performed
in 1888 by Jawdynski [43], a polish surgeon, and the ﬁrst
detaileddescriptionoftheradicalneckdissection(RND)was
published by Crile in 1906 [44]. Interestingly, while 36 of the
132 RNDs described by Crile were en bloc procedures, 96
demonstrated more selective surgical techniques [44]. Crile
recommended preserving the internal jugular vein (IJV)
and sternocleidomastoid muscle (SCM) in a cN0 neck and
advised dissection of only the lymphatic basin draining the
primary tumor if there was no gross disease [44].
Despite the forward thinking of Crile, the en bloc re-
section remained the mainstay for surgical management of
the neck until the mid-1900s. By the early 1950s, Dr. Hayes
Martin and colleagues had performed over 190 NDs, and,
as a staunch defendant of the RND, he disagreed with any
suggestion that the RND be modiﬁed [45]. However, the
signiﬁcant morbidity associated with the RND, especially
related to postoperative shoulder dysfunction, provided
an impetus for research into alternate approaches to the
neck. The discovery that lymphatic structures within fascial
compartments of the neck could be removed without sacri-
ﬁcing nonlymphatic structures [7, 46]p r o m p t e di n v e s t i g a -
tion into more conservative techniques. Ward and Robben
reported the ﬁrst form of a modiﬁed radical neck dissection
(MRND) by in which they spared the spinal accessory nerve
(SAN) [46]. This procedure resulted in decreased shoulder
morbidity without compromising oncologic outcome [17].
MRND was popularized by Bocca, who formally deﬁned
it as the removal of the lymphatic tissue in levels I–
V, with preservation of at least one of the nonlymphatic
structures classically included in RND: IJV, SAN, or SCM
[47]. It was not until the 1960s that authors began reporting
preservation of select lymph node groups, which marked
the ﬁrst formal introduction of the selective neck dissection
(SND) [48]. These advances were supported by the ﬁnding
that metastases from the head and neck tend to follow
fairly constant and predictable pathways, which allows the
surgeon to tailor surgical dissection to target the areas most
at risk [8, 49]. Furthermore, in the 1980s, studies by theISRN Surgery 5
Brazilian Head and Neck Cancer Group found that SND was
equivalent to MRND for the cN0 neck in regards to neck
recurrence rates and long-term survival [50].
As the procedures available for surgical management of
the neck evolved, authors produced a myriad of confusing
and nonsystematic terminology. In 1988, the Committee
for Head and Neck Surgery and Oncology of the American
Academy of Otolaryngology-Head and Neck Surgery called
together a task force in order to simplify terminology, deﬁne
procedures and surgical structures, and classify cervical
metastases based on biology and the principles of surgical
oncology [17]. The outcomes from this meeting with the
recent modiﬁcations made by the Committee for Neck
Dissection Classiﬁcation of the American Head and Neck
Society [51] have resulted in the current classiﬁcation system
used to describe NDs in the modern era.
5.2. Deﬁnitions. T h em o s tb a s i ct e r m su s e dt od e s c r i b e
NDs are deﬁned by surgical intent. The therapeutic ND is
performed for a cN+ neck, while an elective ND is described
for cN0 necks at high risk for occult metastases [7]. In
addition, a staged ND often refers to a planned ND following
primary radiation or chemoradiation therapy while a salvage
ND refers to an ND performed to remove persistent (early
salvage ND)o rr e c u r r e n t( late salvage ND) nodal disease
following nonoperative therapy [7].
The American Head and Neck Society Committee for
Neck Dissection Classiﬁcation described four major cate-
gories of ND currently available based on the anatomic
structures resected (Table 3)[ 51]. These include the radical,
modiﬁed, selective, and extended NDs.
The RND, as ﬁrst described by Crile in 1906, is the
comprehensive standard to which all other dissections are
compared. In this procedure, the SAN, IJV, and SCM are
resected in addition to all lymphatic tissue in levels I–V.
Currently, RND is indicated for patients who have cN+
disease demonstrating ECS with extension to involve the
SAN, IJV, and/or the SCM [17].
The MRND as described initially by Ward and Robben
[46] and further deﬁned by Medina [52] involves en bloc
resection of lymphatic tissue contained in level I–V [7]w i t h
the preservation of one or more nonlymphatic structures
(SAN, IJV, or SCM) [7]. The description of a MRND can be
subclassiﬁed as type I–III depending on the nonlymphatic
structure(s) removed during resection (Table 3)[ 52]. This
dissection is indicated for cN+ disease with no evidence of
extension into the nonlymphatic structures, especially when
multilevel disease is present [7].
The SND has been found to oﬀer an oncologically safe
surgery while decreasing overall morbidity and increasing
functional and cosmetic outcomes for the appropriately se-
lectedpatientpopulation[7].Duringthisdissection,thesur-
geon targets lymph node levels at risk for occult metastases.
This dissection preserves the nonlymphatic structures and
allows the surgeon to tailor the dissection to the primary
tumor and its lymphatic drainage patterns. Because SND
refers to preservation of at least one of the ﬁve neck levels
included in the classical RND, there is signiﬁcant room for
variability. Therefore, authors have deﬁned various terms to
describe diﬀerent techniques, such as the supraomohyoid
SND (levels I–III), lateral SND (level I–IV), posterolateral
SND (level II–V), and the anterior or central SND (level
VI) [2]. While these terms are descriptive in theory, they do
leave room for misinterpretation. Therefore, the Committee
for Head and Neck Surgery and Oncology of the Ameri-
can Academy of Otolaryngology—Head and Neck Surgery
updated the ND classiﬁcation in 2002 and recommended
that each SND should be listed as SND with each variant
depicted with brackets to denote the levels or sublevels
removed [16, 53].
Finally,theextendedNDisemployedwhenthereisahigh
risk or clinical suspicion for metastatic disease outside of the
classic lymph node levels and may be applied to any of the
previously described NDs [17]. Areas targeted by extended
ND may include additional lymph node basins such as
the periparotid, retropharyngeal, parapharyngeal, superior
mediastinal, postauricular, suboccipital, or buccinators [17].
This type of dissection may also target such nonlymphatic
structures as muscle, vasculature, or nerves when at risk or
involved by tumor [17].
5.3. Level IIB and V in OPSCC. The motivation behind
developing more selective ND techniques has been driven in
part by the desire to decrease associated morbidity without
sacriﬁcing oncologic surgical principles and outcomes. The
most signiﬁcant sequelae associated with ND is shoulder
dysfunction and is an important consideration in treatment
of the neck for OPSCC. Taylor et al. looked at quality of
life indicators via the Neck Dissection Impairment Score
and found that the most important variables included age,
weight, radiation treatment, and ND type [54]. Injury of the
S A Nc a nb er e l a t e dt oe x c e s st r a c t i o no re l e v a t i o n[ 18] and is
primarily associated with dissection of levels IIB and V.
RND was classically known to cause denervation of the
trapezius muscle leding to a syndrome of pain, weakness,
and deformity of the shoulder girdle [7]. While Leipzig et
al. [55] showed that any form of ND can result in shoulder
dysfunction, they reported it to occur more frequently when
theSANisworkedaround,skeletonized,orresected.Sobolet
al. compared RND with MRND and predictably found that
patients undergoing RND had signiﬁcantly worse shoulder
outcomes [56]. However, MRND still resulted in associated
shoulder morbidity [56], and the combination of this with
the ﬁnding that SND oﬀered an oncologically safe outcome
in select patients and pushed many surgeons to evaluate the
eﬃcacy of this method. Sobol et al. further demonstrated
that patients undergoing SND (level I–III) had signiﬁcantly
less shoulder dysfunction at 16 weeks postoperatively than
MRND or RND [56]. Chepeha et al. demonstrated a worse
Constant’sShoulderScoreforMRNDthanSNDin32NDsof
each type [57]. Based on these and similar studies, the SND
oﬀers the best chance for preserving shoulder function and
avoiding pain syndromes when the surgeon is able to avoid
dissecting level IIB and V.
Preservation of level IIB in OPSCC is a controversial
topic, as the landmark studies on cervical nodal disease pat-
ternsforOPSCCreportedaveryhighincidenceofmetastatic
disease in level II. However, these studies often did not6 ISRN Surgery
Table 3: Neck dissection deﬁnitions based on lymphatic and nonlymphatic structures resected.
Neck dissection deﬁnition Nonlymphatic structure Lymphatic nodal level Additional∗
SAN IJV SCM I II III IV V VI
Radical x x x x x x x x
MRND ±± ± xxx xx
MRND Type I x x x x x x x
MRND Type II x x x x x x
MRND Type III x x x x x
Complete x x x x x
Selective ±±± ±±
Supraomohyoid x x x
Lateral x x x x
Posterolateral x x x x
Anterior/central x
Extended ±± ± ± ± ± ± ±± x
SAN: spinal accessory nerve; IJV: internal jugular vein; SCM: sternocleidomastoid muscle; I–VI: nodal levels I–VI; MRND: modiﬁed radical neck dissection.
∗Additional: removal of an additional lymph node level/group or nonlymphatic structure not included in a RND. See text for examples.
evaluate the diﬀerence between disease in level IIa and IIB.
InjurytotheSANduringdissectionoflevelIIBcanberelated
to traction, elevation, skeletonization, or ischemia due to
ligation of the occipital artery [18]. The data on involvement
of IIB nodes for all subsites in HNSCC ranges from 0–5.6%
for cN0 cases, and 0–16.7% for cN+ disease [18]. Lee et al.
speciﬁcally analyzed level IIB involvement in OPSCC and
found that 16.7% of ipsilateral and 8.3% of contralateral
level IIB nodal basins were pathologically positive in cN+
disease [18]. In the cN0 neck, 0/36 necks (21 ipsilateral, 15
contralateral) demonstrated disease in level IIB [18]. Based
on these results, they recommended preservation of level IIB
for cN0 OPSCC [18]. Weigand et al. reviewed 77 NDs for
OPSCC and also found that, in the cN0 neck, no patient
was found to have occult Level IIB disease while 25.6% of
cN+ patients had disease in this area [58]. Several other
authors have reported an increased risk for occult IIB disease
in patients demonstrating multiple nodal involvement, most
commonly associated with level II and III disease, as well
as level IIa involvement, high nodal stage, or ECS [18, 59,
60]. Therefore, while preservation of level IIB should be
strongly considered, risk factors for occult metastases should
be thoroughly evaluated in an eﬀort to maintain oncologic
safety.
Preservation of level V in cN0 OPSCC is less contro-
versial, as very few studies have suggested signiﬁcant in-
volvement in this region. In a study of 51 RNDs in 1976,
Skolnik et al. found no metastases to the posterior triangle of
theneckregardlessofprimarysite(larynx,pharynx,andoral
cavity) or the status of the jugulodigastric lymph nodes [61].
In one of the largest retrospective reviews on the subject,
Shah evaluated 1119 RND specimen and found that primary
tumors of the oropharynx predominantly metastasize along
the jugular lymphatic chain (Levels II, III, and IV) [62]. In
addition,regardlessofsubsite,whenlevelsI–IVwerenegative
for occult disease, the posterior cervical triangle was never
involved [62]. This supports Lindberg’s ﬁnding that in the
absence of metastases in levels I and II, involvement of the
low jugular and posterior triangle nodes is exceedingly rare
[8]. Candela et al. also found that while the jugular chain
(level II-III) was the most commonly involved in OPSCC,
nodal involvement in the posterior cervical triangle nodes
was almost always associated with disease at other levels
[63]. They found that only 6% of OPSCC primaries were
associated with posterior cervical triangle disease (level V)
[63]. As detailed above, the incidence of metastatic disease
in level V for OPSCC is relatively low, and therefore there
is a general consensus that if a patient presents with a cN0
neck or a cN+ neck with no evidence of level V disease
and without multilevel involvement, a SND can be safely
performedpreservinglevelVandavoidingdissectionaround
the SAN in this area.
5.4. Surgical Management of the Neck in OPSCC. The choice
of dissection technique for surgical management of the neck
depends on the primary tumor, the clinical status of the
neck, and ultimately on the pathologic status of the neck.
While consideration of primary radiation, chemoradiation
therapy, or observation is beyond the scope of this review,
it is important to remember that management of the neck
is often driven by management the primary tumor for early
staged tumors while multimodal therapy is advocated for
more advanced OPSCC tumors [14, 22].
Understanding the predilection for bilateral cervical
involvement helps guide both evaluation and choice of ND
procedure. Up to 20% of patients with T1 or T2 BOT
OPSCC will have bilateral nodal disease at presentation
[14]. In patients with palatal OPSCC staged T1 or T2 up
to 20% present with cN+ disease, 60–70% of T3 and T4
palatal disease present with regional metastasis [14], and up
to 50% may present with bilateral nodal disease [14, 64].
OPSCC tumors of the PPW often cross midline resulting
in a relatively high risk for bilateral nodal involvement. In
addition, 66–76% of patients with tonsillar OPSCC present
with clinically positive nodal disease, most commonly in
the jugulodigastric nodal group [1, 64, 65]. In tumors thatISRN Surgery 7
involve the true tonsil as well as the posterior tonsillar pillar,
up to 22% have been reported to present with bilateral nodal
involvement, whereas primary tumor growth in the anterior
pillar alone is associated with a 6% risk of bilateral neck
disease [1, 64, 65]. Contralateral necks with evidence of
metastatic spread, or at high risk of metastatic spread, must
beconsideredfordissectionifthetreatmentplanisoperative.
TheNationalComprehensiveCancerNetwork:Headand
Neck Cancer Guidelines [21] have detailed strategies for
the management of OPSCC. For an N0-1 neck associated
with a T1–4 OPSCC primary, the surgical treatment arm
recommends an ipsilateral or bilateral ND as indicated based
on primary tumor risk factors for bilateral involvement
and diagnostic workup [21]. Additional adjuvant chemo-
or radiation therapy is guided by adverse features identiﬁed
intraoperatively, which include ECS, positive margins, pT3
or pT4 primary, N2 or N3 nodal disease, or nodal disease
in levels IV or V [21]. For a patient with N1, N2a-b, or
N3 disease, regardless of T stage, the surgical management
arm includes excision of the primary tumor with ipsilateral
or bilateral ND as indicated while, for any N2c disease,
bilateral ND is mandatory [66]. Again, the presence of ad-
verse risk factors intraoperatively is the key factor in the
recommendationforadjuvanttherapyinthisalgorithm[21].
While the NCCN guidelines provide a helpful framework
for surgical management of OPSCC, they do not provide
recommendations for extent of resection for either the cN0
versus cN+ neck.
ForthecN+neck,dissectiondependsprimarilyonextent
of disease. For patients presenting with gross involvement of
nonlymphatic structures,including the IJV, SAN, or SCM, or
for select cases of bulky, hypomobile nodal disease, a RND
is the procedure of choice [7, 67]. Most institutions will
oﬀer MRND for multilevel or cN+ disease without evidence
of involvement of these structures [7]. At our institution, a
MRND is the procedure of choice for N+ disease. Recently,
there has been some research into the use of SND for some
cN+ patients. Andersen et al. and Spiro et al. have advocated
SND for cN+ necks and reported a regional failure rate
of 5.7% [66, 68], which is consistent with regional failure
rates following RND and MRND [7]. In addition, as the
risk for disease in level V is relatively low for OPSCC, many
authors recommend preservation of level V, especially for
cN1-N2a disease, in order to limit dissection of level V
and thus reduce postoperative morbidity associated with
shoulder dysfunction [67].
In the cN0 neck, it is important to remember that the
consequences of undertreatment are signiﬁcant, and recur-
rence or residual disease in an untreated cN0 neck results
in a poor prognosis [2]. Weiss et al. performed a computer-
assistedmathematicalanalysisofthedecisionsandassociated
outcomes involved in treating the cN0 neck, and concluded
that the beneﬁts of prophylactic treatment of the neck
outweighed costs only when the risk for occult metastases is
greaterthan20%[4].Because15–30%ofpatientsstagedcN0
will develop nodal metastases regardless of OPSCC subsite
or T stage, most authors recommend regional nodal therapy
for all OPSCC primaries [14]. Currently, the SND is the
procedure of choice for the cN0 neck [22]; however, the
extent of resection is controversial. Recommendations vary
from lateral ND (levels I–IV) to a supraomohyoid ND (levels
I–III) [68–70]. Lim et al. reviewed 104 NDs to determine
both the distributions of cervical lymph node metastases
in OPSCC as well as the therapeutic implications for the
N0 neck and recommended that elective ND should include
levels II–IV instead of the more traditional levels I–III [22].
They based this recommendation on the ﬁnding that of 68
patients, who underwent therapeutic ipsilateral ND, 37%
had disease in level IV while only 10% had disease in level
I[ 22]. Shah evaluated 1119 RND specimen and found that
OPSCC predominantly spreads along the jugular lymphatic
chain (Levels II, III, and IV), which also supports the use
of SND (level II–IV) [62]. The decision to dissect level
IIB depends on risk of involvement and is controversial
as described above. In 2004, Coskun et al. advocated the
use of the “susper-selective ND” for some cN0 patients
with OPSCC, which avoids injury to the SAN by preserving
level IIB nodes [71]. At our institution, patients undergoing
surgical management for an N0 neck, regardless of T stage,
will most often receive a SND (level II–IV, including IIB).
The choice to dissect level I depends on several factors,
including the risk of involvement (higher for anterior soft
palate lesions) [7], as well as the preference of the surgeon.
An important consideration when designing an ND for
OPSCC is the status of the retropharyngeal lymph nodes.
This basin is not typically addressed for either the cN0 or
cN+ neck, as seen above. However, RP node involvement is
not uncommon, especially in posterior pharyngeal wall SCC,
and can be associated with poor prognosis [12, 72]. Byers
et al. reported a 4% incidence of RP nodal metastases in
45 patients staged cN0 with pharyngeal wall OPSCC [73],
while Ballantyne reported an incidence as high has 44%
for 34 patients with similar primary tumors [12]. Hasegawa
and Matsuura concluded that since the diagnosis of RP
n o d e si sd i ﬃcult and OPSCC, especially that of the posterior
pharyngeal wall, drains to the RP nodes, management of
these nodes is critical [13]. Therefore, the consideration of
an extended ND to include this lymphatic basin should be
seriously considered when managing both cN0 and cN+
disease.
6. Complications
While we have discussed the oncologic beneﬁts and mor-
bidity associated with ND for OPSCC, one cannot ignore
the acute complications of surgical intervention. The most
dramatic, and often lethal, acute complication is the carotid
artery rupture which is often associated with poor coverage
of vasculature, malnutrition, diabetes, infection, previous
radiation or chemoradiation therapy, and resultant ﬁstula
or ﬂap breakdown [7]. Chyle leak, as a result of level IV
dissection, may occur in treatment of OPSCC and occurs
in up to 2% of patients [7, 74]. Additional complications
such as facial or cerebral edema associated with synchronous
bilateral NDs and IJV ligation, blindness associated with
embolus or hypoperfusion, air embolus from IJV transec-
tion, orocutaneous ﬁstula have all been reported for ND
andshouldbeconsideredwhenindividualizingmanagement8 ISRN Surgery
options [7]. These risks increase with a history of radiation,
chemoradiation, failed surgical therapy, and the presence of
multilevel bulky disease [7].
7. FutureDirection/Conclusions
In recent years, the use of radiation therapy and chemoradia-
tion (CRT) therapy has been used with increasing frequency
as the primary treatment modality for OPSCC tumors.
This leads Kim et al. to hypothesize that there would be a
decrease in the number of NDs performed nationally for
primary HNSCC [75]. However, they found that from 2000
to 2006 there was a slight increase in the point estimates
for ND performed for OPSCC from 2,420 to 2,696, though
this increase was not signiﬁcant [75]. This may be due to
the decision by many surgeons to perform planned ND
either prior to or following CRT or by the use of surgical
intervention alone for small primary tumors cN+ or high-
risk cN0 disease. Based on national trends such as these and
the progressive specialization of ND based on primary site,
surgical management of the neck remains an important and
eﬀective tool and should be considered in the treatment of
the neck in OPSCC.
In an eﬀort to target speciﬁc high-risk nodal groups
and decrease the percentage of patients undergoing ND for
pN0 disease, future study into functional and antibody-
mediated or tumor-directed imaging will be important. In
addition, advancements must be made in molecular studies
which will likely facilitate more eﬀective real time SLN-
directed neck dissections [2, 37]. Finally, surgical techniques
whichminimizemorbiditywithoutcompromisingoncologic
safety, such as endoscopic or robotic techniques, will likely
drive even more selective surgical management of the neck
in OPSCC [76].
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